Abstract:The neurotoxicity associated to the anticancer treatments has received a growing body of interest in the recent years. The development of innovating therapies over the last 20years has led to the emergence of new toxicities. Their diagnosis and management can be challenging in the clinical practice and further research is warranted to improve the understanding of their pathogenic mechanisms. Conventional treatments as radiation therapy and chemotherapy are associated to well-known and under exploration emerging central nervous system (CNS) and peripheral nervous system (PNS) toxicities. The identification of the risk factors and a better understanding of their pathogeny through a "bench to bedside and back again" approach, are the first steps towards the development of toxicity mitigation strategies. New imaging techniques and biological explorations are invaluable for their diagnosis. Immunotherapies have changed the cancer treatment paradigm from tumor cell centered to immune modulation towards an efficient anticancer immune response. The use of the immune checkpoints inhibitors (ICI) and CAR-T cells (chimeric antigen receptor) lead to an increase in the incidence of immune-mediated toxicities and new challenges in the neurological patient's management. The neurological ICI related adverse events (n-irAE) are rare but potentially severe and may present with both CNS and PNS involvement. The most frequent and well characterized, from a clinical and biological standpoint, are the PNS phenotypes: myositis and polyradiculoneuropathy, but the knowledge on CNS phenotypes and their treatments is expanding. The n-irAE management requires a good balance between dampening the autoimmune toxicity without impairing the anticancer immunity. The adoptive cell therapies as CAR-T cells, a promising anticancer strategy, trigger cellular activation and massive production of proinflammatory cytokines inducing frequent and sometime severe toxicity known as cytokine release syndrome and immune effector cell-associated neurologic syndrome. Their management requires a close partnership between oncologist-hematologists, neurologists, and intensivists. The oncological patient's management requires a multidisciplinary clinical team (oncologist, neurologist and paramedical) as well as a research team leading towards a better understanding and a better management of the neurological toxicities.

The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors

Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape

Therapy of leptomeningeal metastasis in solid tumors

The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours

The Role of Neuro-Inflammation and Innate Immunity in Pathophysiology of Brain and Spinal Cord Tumors

The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases

Management of Neurologic Complications in Patients with Brain and Spine Tumors

An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?

Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions

Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases

Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents

Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer

Molecular evolution of central nervous system metastasis and therapeutic implications

Preclinical evaluation of targeted therapies for central nervous system metastases

Contributions of neuroimmune interactions to chemotherapy-induced peripheral neuropathy development and its prevention/therapy

Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors

Current Pharmacological Treatment Approaches to Central Nervous System Leukaemia

Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

Intrathecal dexamethasone and methotrexate treatment of neoplastic meningitis from solid tumors